Population-based epidemiology in Japan reports an increase in therapy-related acute myeloid leukemia (tAML) over three decades, tying the trend to prior chemotherapy and radiation exposure. The study’s updated incidence tracking points to a sustained escalation in a malignancy considered particularly aggressive and difficult to manage once it emerges. Because tAML arises as a delayed consequence of cancer treatment, the findings land at the intersection of oncology survivorship and hematology. The analysis is described as comprehensive and long-running, implying the rise isn’t limited to a narrow time window. Clinically, the work reinforces the need for long-term monitoring strategies after standard anticancer regimens, especially for patients treated with therapies known to carry leukemogenic risk.